The case for autoimmunity in the etiology of schizophrenia

Pharmacotherapy

Volumn 28, Issue 6, 2008, Pages 730-741

  Goldsmith, Carroll Ann W ^a   Rogers, Donald P ^b  

^a MASSACHUSETTS COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^b State Office of Pharmacy Services   (United States)

Author keywords

Autoantibodies; Autoimmunity; Etiology; Immunosuppressants; Immunosuppressive therapy; Schizophrenia

Indexed keywords

AUTOANTIBODY; AUTOANTIGEN; CLOZAPINE; GAMMA INTERFERON; HALOPERIDOL; INTERLEUKIN 2; INTERLEUKIN 4; NEUROTRANSMITTER; OLANZAPINE; PHENOTHIAZINE; RISPERIDONE;

AGRANULOCYTOSIS; ANTIBODY SPECIFICITY; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CYTOKINE RELEASE; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LYMPHOCYTE COUNT; MOLECULAR MIMICRY; MYASTHENIA GRAVIS; NEUROMODULATION; NEUROTRANSMISSION; PATHOGENESIS; REMISSION; REVIEW; SCHIZOPHRENIA;

AUTOANTIBODIES; AUTOANTIGENS; AUTOIMMUNITY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE TOLERANCE; ORGAN SPECIFICITY; SCHIZOPHRENIA;

EID: 47149109049     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.6.730     Document Type: Review

References (84)

1. Saha S, Chant D, Welham J, McGrath J. A systematic review of the prevalence of schizophrenia [online exclusive article]. PLoS Med 2005;2:e141. Available from http://medicine.plosjournals.org/archive/1549-1676/2/5/pdf/10. 1371_journal.pmed.0020141-L.pdf.
2. American Psychiatric Association Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders, 4th edition, text revision (DSM-IV-TR). Washington, DC: American Psychiatric Association, 2000.
3. Opler MG, Susser ES. Fetal environment and schizophrenia. Environ Health Perspect 2005;113:1239-42.
4. Riley B, Kendler KS. Molecular genetic studies of schizophrenia. Eur J Hum Genet 2006;14:669-80.
5. Torrey EF, Leweke MF, Schwarz MJ, et al. Cytomegalovirus and schizophrenia. CNS Drugs 2006;20:879-85.
6. Yao JK, van Kammen DP. Membrane phospholipids and cytokine interaction in schizophrenia. Int Rev Neurobiol 2004;59:297-326.
7. Lehmann-Facius H. Uber die liquordiagnose der schizophrenien. Klin Wochenschr 1937;16:1646-8.
8. Smith DA, Germolec DR. Introduction to immunology and autoimmunity. Environ Health Perspect 1999(107 suppl 5):661-5.
9. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci U S A 1996;93:2264-71.
10. Goodnow CC, Basten A. Self-tolerance in B lymphocytes. Semin Immunol 1989;1:125-35.
11. Hippen KL, Schram BR, Tze LE, Pape KA, Jenkins MK, Behrens TW. In vivo assessment of the relative contributions of deletion, anergy, and editing to B cell self-tolerance. J Immunol 2005;175:909-16.
12. Snider LA, Swedo SE. Post-streptococcal autoimmune disorders of the central nervous system. Curr Opin Neurol 2003;16:359-65.
13. Lie BA, Thorsby E. Several genes in the extended human MHC contribute to predisposition to autoimmune diseases. Curr Opin Immunol 2005;17:526-31.
14. Cannon TD. The inheritance of intermediate phenotypes for schizophrenia. Curr Opin Psychiatry 2005;18:135-40.
15. Jacobson EM, Tomer Y. The genetic basis of thyroid autoimmunity. Thyroid 2007;17:949-61.
16. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves' disease. Thyroid 2007;17:911-22.
17. Levy-Soussan P, Barbouche R, Poirier MF, Galinowski A, Loo H, Avrameas S. A preliminary prospective study on natural autoantibodies and the response of untreated schizophrenic patients to neuroleptics. Biol Psychiatry 1994;35:135-8.
18. Levy-Soussan P, Berneman A, Poirier MF, et al. Differences in the natural autoantibody patterns of patients with schizophrenia and normal individuals. J Psychiatry Neurosci 1996;21:89-95.
19. Sirota P, Firer MA, Schild K, et al. Autoantibodies to DNA in multicase families with schizophrenia. Biol Psychiatry 1993;33:450-5.
20. Ganguli R, Rabin BS, Brar JS. Antinuclear and gastric parietal cell autoantibodies in schizophrenic patients. Biol Psychiatry 1992;32:735-8.
21. Chengappa KN, Ganguli R, Yang ZW, Shurin G, Brar JS, Rabin BS. Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype. Biol Psychiatry 1995;37:546-9.
22. Chengappa KN, Ganguli R, Ulrich R, et al. The prevalence of autoantibodies among right- and left-handed schizophrenic patients and control subjects. Biol Psychiatry 1992;32:803-11.
23. Chengappa KN, Ganguli R, Yang ZW, Brar JS, Li L, Rabin BS. Left-handed first-episode, neuroleptic-naive schizophrenic patients have a higher prevalence of autoantibodies. Schizophr Res 1992;8:75-80.
24. Sirota P, Firer M, Schild K, et al. Increased anti-Sm antibodies in schizophrenic patients and their families. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:793-800.
25. Zorrilla EP, Cannon TD, Gur RE, Kessler J. Leukocytes and organ-nonspecific autoantibodies in schizophrenics and their siblings: markers of vulnerability or disease? Biol Psychiatry 1996;40:825-33.
26. Firer M, Sirota P, Schild K, Elizur A, Slor H. Anticardiolipin antibodies are elevated in drug-free, multiply-affected families with schizophrenia. J Clin Immunol 1994;14:73-8.
27. Wang XF, Wang D, Zhu W, Delrahim KK, Dolnak D, Rapaport MH. Studies characterizing 60 kDa autoantibodies in subjects with schizophrenia. Biol Psychiatry 2003;53:361-75.
28. Schwarz MJ, Riedel M, Gruber R, Muller N, Ackenheil M. Autoantibodies against 60-kDa heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 1998;248:282-8.
29. Schwarz MJ, Riedel M, Gruber R, Ackenheil M, Muller N. Antibodies to heat shock proteins in schizophrenic patients: implications for the mechanism of the disease. Am J Psychiatry 1999;156:1103-4.
30. Mazeh D, Sirota P, Patya M, Novogrodsky A. Antibodies to neuroblastoma cell line proteins in patients with schizophrenia. J Neuroimmunol 1998;84:218-22.
31. Kim JJ, Lee SJ, Toh KY, Lee CU, Lee C, Paik IH. Identification of antibodies to heat shock proteins 90 kDa and 70 kDa in patients with schizophrenia. Schizophr Res 2001;52:127-35.
32. Shcherbakova IV, Siryachenko TM, Mazaeva NA, Kaleda VG, Krasnolobova SA, Klyushnik TP. Leukocyte elastase and autoantibodies to nerve growth factor in the acute phase of schizophrenia and their relationship to symptomatology. World J Biol Psychiatry 2004;5:143-8.
33. Kessler A, Shinitzky M. Platelets from schizophrenic patients bear autoimmune antibodies that inhibit dopamine uptake. Psychobiology 1993;21:299-306.
34. Sinyakov MS, Kessler B, Karp L, Weizman A, Kessler AR. Platelet-associated antibodies mediate protective autoimmune response in schizophrenia. Neuropsychobiology 2003;48:41-6.
35. Reichelt KL, Landmark J. Specific IgA antibody increases in schizophrenia. Biol Psychiatry 1995;37:410-13.
36. Henneberg AE, Horter S, Ruffert S. Increased prevalence of antibrain antibodies in the sera from schizophrenic patients. Schizophr Res 1994;14:15-22.
37. Schott K, Schaefer JE, Richartz E, et al. Autoantibodies to serotonin in serum of patients with psychiatric disorders. Psychiatry Res 2003;121:51-7.
38. Tanaka S, Matsunaga H, Kimura M, et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003;141:155-64.
39. von Kirchbach A, Fischer EG, Kornhuber HH. Failure to detect dopamine receptor IgG autoantibodies in sera of schizophrenic patients: short note. J Neural Transm 1987;70:175-9.
40. Mukherjee S, Mahadik SP, Korenovsky A, Laev H, Schnur DB, Reddy R. Serum antibodies to nicotinic acetylcholine receptors in schizophrenic patients. Schizophr Res 1994;12:131-6.
41. Borda T, Perez Rivera R, Joensen L, Gomez RM, Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 2002;168:3667-74.
42. Borda T, Gomez R, Berria MI, Sterin-Borda L. Antibodies against astrocyte M1 and M2 muscarinic cholinoceptor from schizophrenic patients' sera. Glia 2004;45:144-54.
43. Stevens A, Weller M. Ganglioside antibodies in schizophrenia and major depression. Biol Psychiatry 1992;32:728-30.
44. Geschwind N, Behan P. Left-handedness: association with immune disease, migraine, and developmental learning disorder. Proc Natl Acad Sci U S A 1982;79:5097-100.
45. Coren S. Handedness and allergic response. Int J Neurosci 1994;76:231-6.
46. Morfit NS, Weekes NY. Handedness and immune function. Brain Cogn 2001;46:209-13.
47. von Muhlen CA, Tan EM. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 1995;24:323-58.
48. Shmerling RH. Diagnostic tests for rheumatic disease: clinical utility revisited. South Med J 2005;98:704-11.
49. Knight JG. Dopamine-receptor-stimulating autoantibodies: a possible cause of schizophrenia. Lancet 1982;2:1073-6.
50. Ganzinelli S, Borda T, Sterin-Borda L. Regulation of m1 muscarinic receptors and nNOS mRNA levels by autoantibodies from schizophrenic patients. Neuropharmacology 2006;50:362-71.
51. Schott K, Batra A, Richartz E, et al. Antibrain antibodies in mental disorder: no evidence for antibodies against synaptic membranes. J Neural Transm 1998;105:517-24.
52. Berger A. Th1 and Th2 responses: what are they [commentary]? BMJ 2000;321:424.
53. Ganguli R, Yang Z, Shurin G, et al. Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness. Psychiatry Res 1994;51:1-10.
54. van Kammen DP, McAllister-Sistilli CG, Kelley ME, Gurklis JA, Yao JK. Elevated interleukin-6 in schizophrenia. Psychiatry Res 1999;87:129-36.
55. Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC. Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 2002;57:247-58.
56. Nunes SO, Matsuo T, Kaminami MS, Watanabe MA, Reiche EM, Itano EN. An autoimmune or an inflammatory process in patients with schizophrenia, schizoaffective disorder, and in their biological relatives. Schizophr Res 2006;84:180-2.
57. Sirota P, Schild K, Elizur A, Djaldetti M, Fishman P. Increased interleukin-1 and interleukin-3 like activity in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 1995;19:75-83.
58. Riedel M, Spellmann I, Schwarz MJ, et al. Decreased T cellular immune response in schizophrenic patients. J Psychiatr Res 2007;41:3-7.
59. Schwarz MJ, Kronig H, Riedel M, et al. IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006;256:72-6.
60. Ganguli R, Brar JS, Solomon W, Chengappa KN, Rabin BS. Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production. Psychiatry Res 1992;44:113-23.
61. Schattner A, Cori Y, Hahn T, Sirota P. No evidence for autoimmunity in schizophrenia. J Autoimmun 1996;9:661-6.
62. Ozean ME, Taskin R, Banoglu R, Babacan M, Tuncer E. HLA antigens in schizophrenia and mood disorders. Biol Psychiatry 1996;39:891-5.
63. Jacobsen LK, Mittleman BB, Kumra S, et al. HLA antigens in childhood onset schizophrenia. Psychiatry Res 1998;78:123-32.
64. Tochigi M, Ohashi J, Umekage T, et al. Human leukocyte antigen-A specificities and its relation with season of birth in Japanese patients with schizophrenia. Neurosci Lett 2002;329:201-4.
65. Matsumoto S, Sasaki T, Imamura A, et al. HLA class I distribution in Japanese patients with schizophrenia. Am J Med Genet 2002;114:42-5.
66. Hawi Z, Gibson S, Straub RE, Walsh D, Kendler KS, Gill M. Schizophrenia and HLA: no association with PCR-SSOP typed classical loci in a large Irish familial sample. Am J Med Genet 1999;88:422-9.
67. Laumbacher B, Muller N, Bondy B, et al. Significant frequency deviation of the class I polymorphism HLA-A10 in schizophrenic patients. J Med Genet 2003;40:217-19.
68. Debnath M, Chaudhuri TK. The role of HLA-G in cytokine homeostasis during early pregnancy complicated with maternal infections: a novel etiopathological approach to the neurodevelopmental understanding of schizophrenia. Med Hypotheses 2006;66:286-93.
69. Debnath M, Das SK, Bera NK, Nayak CR, Chaudhuri TK. Genetic associations between delusional disorder and paranoid schizophrenia: a novel etiologic approach. Can J Psychiatry 2006;51:342-9.
70. Glatt SJ, Everall IP, Kremen WS, et al. Comparative gene expression analysis of blood and brain provides concurrent validation of SELENBPI up-regulation in schizophrenia. Proc Natl Acad Sci U S A 2005;102:15533-8.
71. Haider MZ, Zahid MA. Human leukocyte antigen-DQB1 alleles are not associated with schizophrenia in Kuwaiti Arabs. Psychiatry Clin Neurosci 2004;58:236-9.
72. Chowdari KV, Xu K, Zhang F, et al. Immune-related genetic polymorphisms and schizophrenia among the Chinese. Hum Immunol 2001;62:714-24.
73. Schwab SG, Hallmayer J, Freimann J, et al. Investigation of linkage and association/linkage disequilibrium of HLA A-, DQA1-, DQB1-, and DRB1-alleles in 69 sib-pair- and 89 trio-families with schizophrenia. Am J Med Genet 2002;114:315-20.
74. Zai G, King N, Wigg K, et al. Genetic study of the myelin oligodendrocyte glycoprotein (MOG) gene in schizophrenia. Genes Brain Behav 2005;4:2-9.
75. Li T, Underhill J, Liu XH, et al. Transmission disequilibrium analysis of HLA class II DRB1, DQA1, DQB1 and DPB1 polymorphisms in schizophrenia using family trios from a Han Chinese population. Schizophr Res 2001;49:73-8.
76. Raha-Chowdhury R, Andrews SR, Gruen JR. CAT 53: a protein phosphatase 1 nuclear targeting subunit encoded in the MHC class I region strongly expressed in regions of the brain involved in memory, learning, and Alzheimer's disease. Brain Res Mol Brain Res 2005;138:70-83.
77. McAllister CG, Rapaport MH, Pickar D, Paul SM. Effects of short-term administration of antipsychotic drugs on lymphocyte subsets in schizophrenic patients. Arch Gen Psychiatry 1989;46:956-7.
78. Leykin I, Mayer R, Shinitzky M. Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology 1997;37:75-86.
79. Hinze-Selch D, Becker EW, Stein GM, et al. Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology 1998;19:114-22.
80. PGx Health, a Division of Clinical Data. PgxPredict: clozapine test. Available from http://www.pgxhealth.com/genetictests/clozapine/physicians/ faq.cfm. Accessed December 12, 2007.
81. Lencz T, Morgan TV, Athanasiou M, et al. Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol Psychiatry 2007;12:572-80.
82. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. Changes in serum interleukin-2, -6, and -8 levels before and during treatment with risperidone and haloperidol: relationship to outcome in schizophrenia. J Clin Psychiatry 2004;65:940-7.
83. Muller N, Riedel M, Scheppach C, et al. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002;159:1029-34.
84. Bilici M, Tekelioglu Y, Efendioglu S, Ovali E, Ulgen M. The influence of olanzapine on immune cells in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003;27:483-5.